XML 50 R46.htm IDEA: XBRL DOCUMENT
v3.19.3

Certain Transactions - Business Transactions - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions | Jan. 31, 2018 | Oct. 03, 2016 | Aug. 02, 2016 | Mar. 03, 2016
--- | --- | --- | --- | ---
Business Acquisition [Line Items] |  |  |  |
Cash consideration |  | $ 500 | $ 33,400 |
Allergan plc [Member] |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Allergan one time payment to Teva | $ 703 |  |  |
Actavis [Member] |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Shares issued as consideration for the acquisition |  |  | 100.3 |
Rimsa [Member] |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration |  |  |  | $ 2,300

X
- Definition One Time Milestone Payment Received + References No definition available. + Details
Name: | teva_OneTimeMilestonePaymentReceived
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=teva_AllerganPlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ActavisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_RimsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |